NY-UPTIME-INSTITUTE
8.6.2022 12:04:10 CEST | Business Wire | Press release
The digital infrastructure sector is struggling to achieve a measurable reduction in outage rates and severity, and the financial consequences and overall disruption from outages are steadily increasing, according to Uptime Institute , which today released the findings of its 2022 annual Outage Analysis report.
“Digital infrastructure operators are still struggling to meet the high standards that customers expect and service level agreements demand – despite improving technologies and the industry’s strong investment in resiliency and downtime prevention,” said Andy Lawrence, founding member and executive director, Uptime Institute Intelligence .
“The lack of improvement in overall outage rates is partly the result of the immensity of recent investment in digital infrastructure, and all the associated complexity that operators face as they transition to hybrid, distributed architectures,” said Lawrence. “In time, both the technology and operational practices will improve, but at present, outages remain a top concern for customers, investors, and regulators. Operators will be best able to meet the challenge with rigorous staff training and operational procedures to mitigate the human error behind many of these failures.”
Uptime’s annual outage analysis is unique in the industry, and draws on multiple surveys, information supplied by Uptime Institute members and partners, and its database of publicly reported outages.
Key Findings Include :
- High outage rates haven’t changed significantly. One in five organizations report experiencing a “serious” or “severe” outage (involving significant financial losses, reputational damage, compliance breaches and in some severe cases, loss of life) in the past three years, marking a slight upward trend in the prevalence of major outages. According to Uptime’s 2022 Data Center Resiliency Survey, 80% of data center managers and operators have experienced some type of outage in the past three years – a marginal increase over the norm, which has fluctuated between 70% and 80%.
- The proportion of outages costing over $100,000 has soared in recent years. Over 60% of failures result in at least $100,000 in total losses, up substantially from 39% in 2019. The share of outages that cost upwards of $1 million increased from 11% to 15% over that same period.
- Power-related problems continue to dog data center operators. Power-related outages account for 43% of outages that are classified as significant (causing downtime and financial loss). The single biggest cause of power incidents is uninterruptible power supply (UPS) failures.
- Networking issues are causing a large portion of IT outages. According to Uptime’s 2022 Data Center Resiliency Survey, networking-related problems have been the single biggest cause of all IT service downtime incidents – regardless of severity – over the past three years. Outages attributed to software, network and systems issues are on the rise due to complexities from the increasing use of cloud technologies, software-defined architectures and hybrid, distributed architectures.
- The overwhelming majority of human error-related outages involve ignored or inadequate procedures. Nearly 40% of organizations have suffered a major outage caused by human error over the past three years. Of these incidents, 85% stem from staff failing to follow procedures or from flaws in the processes and procedures themselves.
- External IT providers cause most major public outages. The more workloads that are outsourced to external providers, the more these operators account for high-profile, public outages. Third-party, commercial IT operators (including cloud, hosting, colocation, telecommunication providers, etc.) account for 63% of all publicly reported outages that Uptime has tracked since 2016. In 2021, commercial operators caused 70% of all outages.
- Prolonged downtime is becoming more common in publicly reported outages. The gap between the beginning of a major public outage and full recovery has stretched significantly over the last five years. Nearly 30% of these outages in 2021 lasted more than 24 hours, a disturbing increase from just 8% in 2017.
- Public outage trends suggest there will be at least 20 serious, high-profile IT outages worldwide each year. Of the 108 publicly reported outages in 2021, 27 were serious or severe. This ratio has been fairly consistent since the Uptime Intelligence team began cataloging major outages in 2016, indicating that roughly one-fourth of publicly recorded outages each year are likely to be serious or severe.
Learn More : For further insight into Uptime’s latest research on digital infrastructure failures, register to attend the upcoming 2022 Outage Report webinar on Thursday, June 16th at 9:00 a.m. PDT here .
The complete report is available exclusively for the Uptime Institute Membership Network, the world’s largest group of data center owners and operators. Learn more about Uptime Institute Membership and request a free guest trial here .
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. Its Tier Standard is the IT industry’s most trusted and adopted global standard for the proper design, construction, and operation of data centers – the backbone of the digital economy. For over 25 years, the company has served as the standard for data center reliability, sustainability, and efficiency, providing customers assurance that their digital infrastructure can perform at a level that is consistent with their business needs across a wide array of operating conditions. With its data center Tier Standard & Certifications, Management & Operations reviews, broad range of related risk and performance assessments, and accredited educational curriculum completed by over 10,000 data center professionals, Uptime Institute has helped thousands of companies, in over 100 countries to optimize critical IT assets while managing costs, resources, and efficiency.
Uptime Institute is headquartered in New York, NY, with offices in Seattle, London, Sao Paulo, Dubai, Singapore, and Taipei and staff in over 25 other countries. For more information, please visit www.uptimeinstitute.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005265/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
